Biotech Values

[DewDiligence]

Roche ITMN VRUS etc. – If Pegusus is bringing in some decent cash right now, does it make sense for Roche to do an all-oral antiviral cocktail trial so they can lose that Pegusus revenue?

Yes—it makes a lot of sense. If they don’t do it, someone else will.